COL8A1 as a pro-inflammatory mediator bridges immune evasion and therapy resistance in glioma
By connecting tumor-intrinsic inflammation to immunological surveillance and treatment resistance, our study identified COL8A1 as a crucial inflammatory hub in glioma. In order to improve the results of immunotherapy for glioma, COL8A1 may be a useful therapeutic target and prognostic biomarker.
Authors
- Jiale Li (ORCID: https://orcid.org/0009-0000-3234-5626)
- Jiachong Wang
- Changfeng Miao
- Chunyuan Zhang (ORCID: https://orcid.org/0000-0001-8297-9803)
- Jun Peng (ORCID: https://orcid.org/0000-0003-2590-0024)
- Qisheng Luo (ORCID: https://orcid.org/0009-0007-7152-4759)
- Zigui Chen (ORCID: https://orcid.org/0000-0001-6538-7830)
- Chunhai Tang
Institutions
- Central South University (CN)
- Guangxi Medical University (CN)
- Hunan Normal University (CN)
- Haikou City People's Hospital (CN)
- First Affiliated Hospital of GuangXi Medical University (CN)
- Affiliated Hospital of Youjiang Medical University for Nationalities (CN)
- Baise University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-12-10
- DOI
- https://doi.org/10.3389/fimmu.2025.1727298
- Primary Topic
- Glioma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00